Saw this posted by barsax over on SH:

In compliance with the Securities and Exchange Commission's Regulation FD (Fair Disclosure), the accepted abstracts are made available to the public on the NKF website and are published in AJKD, ACKD, JRN, or JNSW (dependent on discipline) in advance of the meeting. Thus, the first release of the abstracts is a public release. Coverage of additional research being presented at the NKF Spring Clinical Meetings is under embargo until 8:00am on Friday, March 27, 2020.

Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract. However, the NKF continues to require that information that goes beyond that contained within the abstract, e.g., discussion of the abstract done as part of a scientific presentation, is to be embargoed until the start of the Meetings. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Journalists failing to abide by the embargo may have their press credentials revoked.

(All bolding for emphais is mine)

https://www.kidney.org/spring-clinical/abstract-embargo